BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.

Lijie XingSu WangJiye LiuTengteng YuHailin ChenKenneth WenYuyin LiLiang LinPhillip A HsiehShih-Feng ChoGang AnLugui QiuKrista KinneerNikhil MunshiKenneth C AndersonYu-Tzu Tai

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

These results provide the basis for clinical evaluation of combination MEDI2228 with Dara to further improve patient outcome in multiple myeloma.

Keyphrases

multiple myeloma
immune response
poor prognosis
dendritic cells
case report
toll like receptor
diffusion weighted
binding protein
cancer therapy
diffusion weighted imaging
computed tomography
inflammatory response
drug delivery
contrast enhanced
nk cells